The primary purpose of this medication is to provide supportive, short-term symptomatic assistance during acute episodes of cold and flu, addressing symptoms that interfere with daily functioning. These combination products are commonly used for conditions presenting with systemic or localized discomfort.

This preparation is generally used across therapeutic domains where additional symptomatic support is needed. These domains include managing elevated body temperature (fever), and helping address aches and pains, headache, and nasal and sinus congestion. It is relevant for symptoms that create noticeable physiological strain like nasal stuffiness and sinus pressure, and is applied when these symptom clusters interfere with daily comfort. The application of this medication assists with maintaining functional stability and supports the patient's ability to cope more steadily with difficult manifestations. The combination is helpful in situations where multiple symptoms occur together and become temporarily overwhelming.

---

Quick Fact: Relief for Fever, Pain, and Congestion

---

Regulatory References

1. Label: DAYTIME NIGHTTIME COLD AND COUGH- acetaminophen, dextromethorphan hbr, phenylephrine hcl, doxylamine succinate kit - DailyMed

Eligibility Scope

Population Status	Regulatory Rule
Allowed	Adults and adolescents aged 12 years and over.
Not Recommended	Children under 12 years of age, pregnant women, and breastfeeding women.

Contraindicated Populations (Must Not Use)

Official regulatory documents explicitly contraindicate the use of Coldrex MaxFrip in individuals with the following conditions:

• Severe Organ Dysfunction: Severe liver failure (hepatic insufficiency) or severe kidney failure (renal impairment).
• Cardiovascular/Metabolic: Severe hypertension (high blood pressure), heart disease, hyperthyroidism (overactive thyroid), or diabetes.
• Hypersensitivity: Known allergy to paracetamol, phenylephrine, ascorbic acid, or any component.
• Concurrent Drug Use: Patients taking Monoamine Oxidase Inhibitors (MAOIs) or who have taken them within the last two weeks, or those taking other sympathomimetic decongestants or other paracetamol-containing products.
• Other Conditions: Narrow-angle glaucoma, chronic alcoholism, or phaeochromocytoma.

Eligibility-Related Restrictions

Conditional use is required for certain populations. Patients with moderate renal impairment may require an extended interval between doses. Caution is also advised for those with prostate problems, specific blood vessel diseases (like Raynaud's phenomenon), or those on a sodium-controlled diet due to excipient content.

This combination medication, which contains paracetamol, phenylephrine, and ascorbic acid (Vitamin C), can interact with various other medicines. It is essential to consult a healthcare provider before use, particularly if taking prescription drugs.

Major Contraindications

Do not take Coldrex MaxFrip if you are currently taking or have taken any of the following medicines within the last two weeks, as these combinations can lead to dangerous reactions, including hypertensive crisis or cardiovascular complications:

• Monoamine Oxidase Inhibitors (MAOIs): Used for depression and psychiatric conditions.
• Other Sympathomimetic Agents: Including other decongestants, appetite suppressants, and certain stimulants.

Significant Drug Interactions

Consult a doctor if you are taking any of the following, as dosage adjustments or careful monitoring may be necessary:

Active Ingredient	Interaction Risk/Mechanism
Paracetamol
Other Paracetamol-Containing Products	Risk of overdose and severe liver damage. Avoid entirely.
Warfarin and other Coumarins	Prolonged, regular use can enhance the anticoagulant effect and increase bleeding risk.
Metoclopramide, Domperidone	May increase the speed of paracetamol absorption.
Colestyramine	May decrease the absorption of paracetamol.
Phenylephrine
Beta-blockers / Other Antihypertensives	May reduce the effectiveness of these blood pressure-lowering drugs and increase the risk of hypertension.
Tricyclic Antidepressants (e.g., Amitriptyline)	Increased risk of cardiovascular side effects.
Digoxin / Cardiac Glycosides	Increased risk of irregular heartbeat or heart attack.

Other Considerations

Avoid consuming large amounts of alcohol while taking this medicine, as alcohol increases the risk of paracetamol-induced liver damage. Excessive intake of caffeine from beverages like coffee or tea should also be limited due to the potential for increased stimulant effects from phenylephrine.

Modulation of Central Prostaglandin Synthesis and Nociception

Acetaminophen acts as an enzyme inhibitor predominantly within the Central Nervous System. Its mechanism reduces the synthesis of Prostaglandin E2 (PGE2) in the hypothalamus by interfering with the Cyclooxygenase (COX) pathway . This molecular action influences the body's thermoregulatory set-point and reduces the excitability of central nociceptive pathways, leading to a physiological decrease in core body temperature and a dampened response in the pain signaling cascade.

---

Selective Control of Nasal and Sinus Vascular Tone

The systemic component, Phenylephrine, exerts its action as a direct agonist on Alpha-1 (alpha1) Adrenergic Receptors located on the vascular smooth muscle of the nasal and sinus lining . This targeted receptor activation triggers immediate vasoconstriction, a physiological change that induces vasoconstriction and reduces blood volume in the mucosa. This process reduces capillary hydrostatic pressure and limits fluid exudation in the affected tissue.

---

Complementary Mechanism and Cellular Redox Support

The final component, Ascorbic Acid, functions as a key biological cofactor and modulates the cellular redox system. Its action supports metabolic and cellular defense processes, which is relevant for the maintenance of normal cellular redox state.

The administration of Coldrex MaxFrip is governed by a defined regulatory protocol for oral use as an aqueous solution. The standard single dose for adults and adolescents is one sachet, which delivers 1000 mg of the analgesic component. This fixed-dose combination product is designated for use on an as-needed (PRN) basis to address concurrent symptoms.

Official dosing schedules require a minimum interval of four hours between successive doses to prevent exceeding the regulatory limit of four sachets (4000 mg Paracetamol) in any 24-hour period. Procedurally, the powder contents of one sachet must be completely dissolved by mixing with hot water and consumed as a solution. Taking the preparation after a meal may be associated with a decrease in the rate of absorption of the analgesic component.

The official usage protocol includes constraints regarding duration and population. The medication is intended solely for short-term treatment and must not be used continuously for more than seven days without medical review. Furthermore, the minimum dose interval must be formally extended for patients with renal impairment: specifically, to 6 hours for moderate impairment and 8 hours for severe impairment. A mandatory procedural condition requires the patient to avoid co-administration with any other medicinal products containing paracetamol or other systemic decongestants.

Overview of Studies for Coldrex MaxFrip

This section will outline the structure of the clinical research supporting the fixed-dose combination, focusing on the types of studies that exist, the outcomes they measured, and the limitations documented in the scientific and regulatory record. Research does not determine whether an individual will respond similarly; findings describe group patterns, not personal outcomes.

---

Evidence for Symptomatic Relief of Common Cold and Flu-like Illness

This section will summarize the short-term Randomized Controlled Trials (RCTs) and systematic reviews that have evaluated the combination's effect on the overall cluster of symptoms, including fever, generalized pain, and nasal congestion, as reported by study participants.

Research has explored how symptoms change over time in patients experiencing acute and disruptive episodes of common cold and flu-like illness. Studies conducted during periods of increased symptom activity have primarily used short-term Randomized Controlled Trials (RCTs). Findings describe patterns observed in the studies related to the overall relief of the combined symptom cluster, such as fever, headache, and nasal congestion. However, evidence highlights that reported outcomes were short-term, and findings were mixed regarding the patterns of relief for specific individual symptoms.

Types of Studies and Outcomes Examined

This part will detail the specific study designs, such as placebo-controlled trials, pharmacokinetic studies, and meta-analyses, and will describe the measurement tools used by researchers, including Total Symptom Scores and subjective ratings for individual physical symptoms.

Clinical research has relied on several methodologies to evaluate this combination. Evidence includes Systematic Reviews and Meta-analyses and Pharmacokinetic (PK) studies, which examine how the active components are absorbed together. Research examined outcomes related to physical discomfort and acute changes, using tools like Total Symptom Scores (TSS) and subjective scoring systems to measure patient-reported discomfort.

Study Duration and Characterization of Short-Term Data

The research exploring short-term symptom changes is characterized by limited follow-up durations. The majority of the studies conducted during periods of increased symptom activity utilized an observation period of 48 to 72 hours, or up to five days. These follow-up durations were limited by the self-limiting nature of the common cold itself, meaning findings primarily reflect the acute phases of illness.

Research in Specific Populations

This section will outline which groups were included in the clinical research, focusing on the characteristics of the primary adult population studied and noting any available data for subgroups.

The available research primarily involved otherwise healthy Adults (18 to 60 years) diagnosed with conditions characterized by acute or disruptive episodes. Data for certain groups remain insufficient. For example, there is limited information for long-term outcomes or how findings might apply to older adults or individuals with pre-existing conditions (comorbidities).

Documented Research Gaps and Uncertainties

This final part will synthesize the limitations cited in the scientific record, including the lack of long-term outcome data, variability in findings across different trials, and specific evidence gaps concerning the effectiveness of the oral decongestant component.

Research highlights what is known, but evidence also indicates areas where certainty remains low. One key limitation is that follow-up durations were limited, meaning long-term effects are not fully established. Furthermore, scientific literature and regulatory discussions cite a research gap concerning the consistent evidence for oral phenylephrine at typical doses in managing nasal congestion. Comparative evidence is lacking for certain specific trial designs.

Common questions about Coldrex MaxFrip (FAQ)

---

Q: What is the recommended storage temperature for this medicine, and what should I do if I forget a dose?

Official product information states that this medicine is generally recommended to be stored at room temperature, specifically between 20 C and 25 C (68 F and 77 F). Information regarding how to handle a missed dose is available within the Dosage and Administration section of the full prescribing information.

---

Q: Does this medicine cause drowsiness or make me sleepy?

Official drug labeling indicates that somnolence (a medical term for feeling drowsy or sleepy) and dizziness have been reported as adverse reactions. The labeling advises that due to potential Central Nervous System (CNS) effects, caution should be exercised regarding activities that require mental alertness, such as driving or operating heavy machinery.

---

Q: Can children who are 2 years old use this medicine?

The official product information defines the specific age range for which this medicine has been studied and approved for use in children. If the age of 2 years old is not covered by the defined approved population, the official label indicates that the safety and effectiveness of the medicine have not been studied or confirmed for use in children that age.

Official Storage and Disposal Requirements

Official regulatory information for Coldrex MaxGrip powder for oral solution defines mandatory environmental and handling conditions to maintain product stability and safety.

Storage Condition	Requirement
Temperature	Must be stored below 30 C.
Expiration	Do not use after the expiry date indicated on the carton and sachet.
Child Safety	Keep out of the reach of children.

For disposal, the regulatory mandates are explicit: the product must not be discarded via household waste or flushed into wastewater. Unused or expired Coldrex MaxGrip must be disposed of according to local pharmaceutical waste and environmental requirements to ensure proper handling.